Literature DB >> 2411132

Laboratory tests and diagnostic procedures in evaluation of liver disease.

S Chopra, P H Griffin.   

Abstract

Evaluation of liver disease can be a difficult and imposing problem for general internists and noninternists alike. Physicians are often faced with a confusing array of what are commonly referred to as "liver function tests"; indeed, with the advent of and commonplace use of automated serum testing batteries, these findings are increasingly frequent in asymptomatic persons. Abnormalities in liver function are occasionally discovered incidentally when the testing battery is performed without suggestion of liver disease. There are numerous examples of algorithms and flow diagrams designed with an aim toward aiding clinicians in completion of an adequate diagnostic evaluation when faced with a particular set of abnormalities on "liver function tests." However, a clearer understanding of these tests and others, which are in a broader sense tests of liver function, might be of greater value than such a systematic and regimented approach to the evaluation of liver disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411132     DOI: 10.1016/0002-9343(85)90013-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

Review 1.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

2.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

3.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

4.  Serum concentrations of laminin in cirrhosis of the liver.

Authors:  J Collazos; F Díaz; J Genollá
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

5.  Seroprevalence of subclinical HEV infection in asymptomatic, apparently healthy, pregnant women in Dakahlya Governorate, Egypt.

Authors:  Yahia Z Gad; Nasser Mousa; Maher Shams; Ahmed Elewa
Journal:  Asian J Transfus Sci       Date:  2011-07

6.  Increased α-Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4.

Authors:  Nasser Mousa; Yahia Gad; Azza Abdel-Aziz; Ibrahem Abd-Elaal
Journal:  Int J Hepatol       Date:  2012-05-14

7.  Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B.

Authors:  Ghodrat Montazeri; Arezoo Estakhri; Mehdi Mohamadnejad; Negin Nouri; Farhad Montazeri; Ashraf Mohammadkani; Mohammad Hossain Derakhshan; Farhad Zamani; Shahram Samiee; Reza Malekzadeh
Journal:  BMC Gastroenterol       Date:  2005-10-12       Impact factor: 3.067

8.  Medical and Surgical Conditions for the Treatment of Malabsorption.

Authors:  Wolfgang Fischbach; Oliver Al-Taie; Christoph Dietrich; Jörg Felber; Kerstin Schütte; Michael Schumann
Journal:  Viszeralmedizin       Date:  2014-06-16

9.  Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma.

Authors:  Jin Soo Bae; Sang Jong Park; Kwang Bo Park; So Ya Paik; Jin Kyung Ryu; Chang Kyu Choi; Tae Joon Hwang
Journal:  Korean J Intern Med       Date:  2005-03       Impact factor: 2.884

10.  A clinical and immunological study of children with chronic hepatitis B virus infection.

Authors:  Mortada El-Shabrawi; Manal Abdelgawad; Ola Elgaddar; Fetouh Hassanin; Ahmed Khalil; Aml Mahfouz; Basant Elbanna
Journal:  Prz Gastroenterol       Date:  2019-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.